Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Income towards Parent Company (2021 - 2025)

Valion Bio has reported Income towards Parent Company over the past 5 years, most recently at -$2.5 million for Q3 2025.

  • For Q3 2025, Income towards Parent Company fell 73.24% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached -$5.9 million, down 3.64%, while the annual FY2024 figure was $5.7 million, 169.14% up from the prior year.
  • Income towards Parent Company for Q3 2025 was -$2.5 million at Valion Bio, down from -$1.9 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$1.2 million in Q3 2021 and troughed at -$3.0 million in Q2 2022.
  • A 5-year average of -$1.9 million and a median of -$1.9 million in 2025 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: crashed 136.15% in 2022 and later surged 37.6% in 2024.
  • Year by year, Income towards Parent Company stood at -$2.3 million in 2021, then rose by 1.57% to -$2.3 million in 2022, then rose by 0.53% to -$2.2 million in 2023, then skyrocketed by 34.36% to -$1.5 million in 2024, then tumbled by 68.3% to -$2.5 million in 2025.
  • Business Quant data shows Income towards Parent Company for TIVC at -$2.5 million in Q3 2025, -$1.9 million in Q2 2025, and -$1.5 million in Q1 2025.